FDA Panel To Mull Risks Of Amgen’s Enbrel For Pediatric Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s Dermatologic and Ophthalmic Drugs Advisory Committee also will discuss whether the sponsor submitted sufficient information to extend approval to the pediatric population.
You may also be interested in...
FDA Committee Recommends Amgen’s Enbrel For Approval In Pediatric Psoriasis
Panel sees benefit of giving physicians freedom to choose the treatment and gaining further data through Amgen’s proposed safety registry and ongoing study.
FDA Committee Recommends Amgen’s Enbrel For Approval In Pediatric Psoriasis
Panel sees benefit of giving physicians freedom to choose the treatment and gaining further data through Amgen’s proposed safety registry and ongoing study.
Anti-TNFs’ Link To Cancer In Children Under Investigation By FDA
Agency is investigating approximately 30 reports of cancer in pediatric patients.